Identification of Aberrant Promoter Hypomethylation of HOXA10 in Ovarian Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2010 Feb 13

PMID 20151152

Citations 19

Authors

Wenjun Cheng

Yi Jiang

Cuixia Liu

Ouxi Shen

Weiwei Tang

Xinru Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to determine the relationship between hypomethylation of HOXA10 gene's promoter and high expression in malignant ovarian tissues, and to confirm the level of hypomethylation in ovarian cell lines.

Experimental Design: We performed the methylation status of 29 samples from ovarian carcinomas and 16 from normal tissues by methylation-specific polymerase chain reaction (MSP). Then, we evaluated the expression of mRNA and protein of HOXA10 in all samples to work out the relationship between the methylation status of HOXA10 and its expression in transcriptional and translational levels. We then confirmed our present study using SKOV3 and HEY ovarian cancer cell lines treated with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) to detect whether the expression of HoxA10 in the two cell lines was altered.

Results: Increased expression of HOXA10 was detected in almost all ovarian carcinomas (p < 0.05). Promoter hypomethylation was found in (17 of 29) 58.62% ovarian cancers and (4 of 16) 25% normal ovaries (p < 0.05). The HOXA10 expression is higher when the status of HOXA10 gene promoter is hypomethylated than in methylated tissues (p < 0.05). After 5-aza-dC treatment, the expression level of HOXA10 mRNA transcript was increased in the two cell lines.

Conclusion: Our results indicate that promoter hypomethylation is an important mechanism for high expression of HOXA10 in human ovarian cancer and may be a potential prognostic factor in ovarian cancer.

Citing Articles

[A two-site combined prediction model based on HOXA9 DNA methylation for early screening of risks of meningioma progression].

Tan R, Bao X, Han L, Li Z, Tian N Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(11):2110-2120.

PMID: 39623266 PMC: 11605192. DOI: 10.12122/j.issn.1673-4254.2024.11.07.

Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review).

Silva-Hurtado T, Inocencio J, Yong R Mol Clin Oncol. 2024; 21(3):59.

PMID: 39006906 PMC: 11240870. DOI: 10.3892/mco.2024.2757.

Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically resected pancreatic cancer patients.

Yang J, Tang Y, Wang J, Yu C, Li H, Yi B Gland Surg. 2022; 11(10):1697-1711.

PMID: 36353587 PMC: 9638791. DOI: 10.21037/gs-22-517.

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Singh A, Gupta S, Sachan M Front Cell Dev Biol. 2019; 7:182.

PMID: 31608277 PMC: 6761254. DOI: 10.3389/fcell.2019.00182.

HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1.

Zhang Y, Chen J, Wu S, Lv M, Yu Y, Tang Z Cancer Manag Res. 2019; 11:7065-7076.

PMID: 31440094 PMC: 6666378. DOI: 10.2147/CMAR.S199239.

References

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Szyf M, Pakneshan P, Rabbani S . DNA demethylation and cancer: therapeutic implications. Cancer Lett. 2004; 211(2):133-43. DOI: 10.1016/j.canlet.2004.04.009. View

Jones P, Takai D . The role of DNA methylation in mammalian epigenetics. Science. 2001; 293(5532):1068-70. DOI: 10.1126/science.1063852. View

Shen J, Rideout 3rd W, Jones P . High frequency mutagenesis by a DNA methyltransferase. Cell. 1992; 71(7):1073-80. DOI: 10.1016/s0092-8674(05)80057-1. View

Kelly M, Daftary G, Taylor H . An autoregulatory element maintains HOXA10 expression in endometrial epithelial cells. Am J Obstet Gynecol. 2006; 194(4):1100-7. DOI: 10.1016/j.ajog.2005.12.025. View

Feinberg A, Vogelstein B . Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301(5895):89-92. DOI: 10.1038/301089a0. View

Cheng W, Liu J, Yoshida H, Rosen D, Naora H . Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005; 11(5):531-7. DOI: 10.1038/nm1230. View

Issa J . CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol. 2000; 249:101-18. DOI: 10.1007/978-3-642-59696-4_7. View

Das P, Singal R . DNA methylation and cancer. J Clin Oncol. 2004; 22(22):4632-42. DOI: 10.1200/JCO.2004.07.151. View

10.

Lechner J, Fugaro J, Wong Y, Pass H, Harris C, Belinsky S . Perspective: cell differentiation theory may advance early detection of and therapy for lung cancer. Radiat Res. 2000; 155(1 Pt 2):235-238. DOI: 10.1667/0033-7587(2001)155[0235:pcdtma]2.0.co;2. View

11.

Daftary G, Troy P, Bagot C, Young S, Taylor H . Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol. 2002; 16(3):571-9. DOI: 10.1210/mend.16.3.0792. View

12.

Miller G, Miller H, Van Bokhoven A, Lambert J, Werahera P, Schirripa O . Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003; 63(18):5879-88. View

13.

Pakneshan P, Szyf M, Farias-Eisner R, Rabbani S . Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 2004; 279(30):31735-44. DOI: 10.1074/jbc.M401669200. View

14.

Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D . LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 18(4):711-7. DOI: 10.1111/j.1525-1438.2007.01117.x. View

15.

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

16.

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

17.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

18.

Fraga M, Agrelo R, Esteller M . Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci. 2007; 1100:60-74. DOI: 10.1196/annals.1395.005. View

19.

Swanton C, Nicke B, Downward J . RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?. Lancet Oncol. 2004; 5(11):653-4. DOI: 10.1016/S1470-2045(04)01604-3. View

20.

Shi H, Wang M, Caldwell C . CpG islands: their potential as biomarkers for cancer. Expert Rev Mol Diagn. 2007; 7(5):519-31. DOI: 10.1586/14737159.7.5.519. View